Sintilimab plus Chemotherapy
Phase 3Small molecule
Sintilimab plus Chemotherapy is one of 67 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.
4
Indications
5
Total Trials
3
Active Trials
66
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
414 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Carboplatin Plus Paclitaxel
BayerPhase 3
HB1801
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 3
Sintilimab plus Chemotherapy
FFudan University
Phase 3
Consolidative Therapy
SSun Yat-sen University
Phase 3
HLX17
Shanghai Henlius BiotechPhase 3
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Adjuvant Treatment1 trial
Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ
Recruiting·—·Phase 2·NCT06761846·70 enrolled
Non-Small Cell Lung Cancer1 trial
Transplantation1 trial
Intestinal Microbiota Transplantation, Radiochemotherapy and Sintilimab in Localized Advanced Colon Cancer
Enrolling by invitation·FFirst Affiliated Hospital of Ningbo University·Phase 4·NCT06931808·20 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- FFudan University